CSF3 and myocardial infarction: Treatment with recombinant G-CSF has been under examination after myocardial infarction and a large number of clinical trials have tested its effects on myocardial infarct size.[4] It is suspected to prevent left ventricular remodeling and dysfunction after myocardial infarction; it may improve chronic myocardial ischemia and stimulates re-endothelialization after vessel-injury in animal models.